Submitted by Sabin on
July 7, 2004
Submitted by Sabin on
NEW CANAAN, CT — Fever, cough, aches and chills mean one thing to most of us as the winter months draw near—influenza, the flu, is circulating again in our community. If we could avoid the misery and potential complications, most of us would choose to do so. Each year, we hope there will be plentiful vaccine, yet once again we have scarce supply.
Submitted by Sabin on
COLD SPRING HARBOR, NY — Health experts wrapped up a meeting here Tuesday to formulate recommendations for vaccine policy in the event of a pandemic flu outbreak. The group acknowledges that routine annual influenza epidemics would be overshadowed by the looming calamity posed by a pandemic influenza event.
Submitted by Sabin on
NEW CANAAN, CT —Recent highly publicized vaccine shortages have cast a shadow over the otherwise enormous success of vaccines as a tool for disease prevention around the world. Vaccines have been the cornerstone of public health for the past 50 years and shortages have shaken public confidence and exposed real vulnerabilities in the current system of vaccines production.
Submitted by Sabin on
NEW CANAAN, CT, October 18, 2004 —The Institute of Medicine (IOM) of the National Academies today announced the election of 65 new members, including Sabin Vaccine Institute (Sabin) Director of International Programs Ciro de Quadros, MD, MPH. New members bringing the roster to 1,416 also included Sabin trustee Michael T. Osterholm, PhD and scientific advisor Stephen L. Hoffman, M.D.
Submitted by Sabin on
NEW CANAAN, CT — A global flu outbreak—flu pandemic—strikes three or four times in a century, with a new strain of flu met by weak immune resistance around the globe. The pandemic flu of 1918 killed 40 million people; at least two lesser pandemics occurred in the last half of the 20th century.
Submitted by Sabin on
NEW CANAAN, CT, September 15, 2004—The Sabin Vaccine Institute, sponsor of research funded by the Bill & Melinda Gates Foundation on a newly developed vaccine to prevent human hookworm disease, has signed a memorandum of understanding with federal and state vaccine production facilities in Brazil for clinical development of the vaccine, including clinical trials and vaccine manufacture.
Submitted by Sabin on
NEW CANAAN, CT, August 19, 2004—An article published today in The New England Journal of Medicine calls attention to the enormous impact of parasitic hookworm infection on the developing world poor. The authors of “Current Concepts: Hookworm Infection” have studied the parasite over many years and describe the disturbing effects of mild infection as well as the disease state that results from heavy hookworm infection.